Show simple item record

dc.contributor.authorTrovik, Joneen_US
dc.contributor.authorWik, Elisabethen_US
dc.contributor.authorWerner, Henrica Maria Johannaen_US
dc.contributor.authorKrakstad, Camillaen_US
dc.contributor.authorHelland, Haralden_US
dc.contributor.authorVandenput, Ingriden_US
dc.contributor.authorNjølstad, Tormund Salvesenen_US
dc.contributor.authorStefansson, Ingunnen_US
dc.contributor.authorMarcickiewicz, Januszen_US
dc.contributor.authorTingulstad, Solveigen_US
dc.contributor.authorStaff, Anne Cathrineen_US
dc.contributor.authorAmant, Frédéricen_US
dc.contributor.authorAkslen, Lars A.en_US
dc.contributor.authorSalvesen, Helga Birgitteen_US
dc.description.abstractBackground: Preoperative histologic examination of tumour tissue is essential when deciding if endometrial cancer surgery should include lymph node sampling. We wanted to investigate if biomarkers could improve prediction of lymph node metastasis and outcome. Patients and methods: Curettage specimens from 832 endometrial carcinoma patients prospectively recruited from 10 centres in the MoMaTEC trial (Molecular Markers in Treatment of Endometrial Cancer) were investigated for hormone receptor and p53 status. Results: Eighteen per cent of tumours were double negative for oestrogen- and progesterone receptors (ER/PR loss), 24% overexpressed p53. Pathologic expression of all markers correlated with nodal metastases, high FIGO (Federation International of Gynecology and Obstetrics) stage, non-endometrioid histology, high grade and poor prognosis (all P < 0.001). ER/PR loss independently predicted lymph node metastasis (odds ratios (OR) 2.0, 95% confidence interval (CI) 1.1–3.7) adjusted for preoperative curettage histology and predicted poor disease-specific survival adjusted for age, FIGO stage, histologic type, grade and myometrial infiltration (hazard ratio (HR) 2.3, 95% CI 1.4–3.9). For lymph node negative endometrioid tumours, ER/PR loss influenced survival independent of grade. Conclusion: Double negative hormone receptor status in endometrial cancer curettage independently predicts lymph node metastasis and poor prognosis in a prospective multicentre setting. Implementing hormone receptor status to improve risk-stratification for selecting patients unlikely to benefit from lymphadenectomy seems justified.en_US
dc.rightsAttribution-NonCommercial-NoDerivs CC BY-NC-NDeng
dc.subjectEndometrial cancereng
dc.subjectHormone receptorseng
dc.subjectLymph node metastaseseng
dc.titleHormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trialen_US
dc.typePeer reviewed
dc.typeJournal article
dc.rights.holderCopyright 2013 The Authors
dc.source.journalEuropean Journal of Cancer
dc.relation.projectNorges forskningsråd: 193373
dc.relation.projectNorges forskningsråd: 223250
dc.relation.projectNorges forskningsråd: 205404
dc.subject.nsiVDP::Medical sciences: 700::Clinical medical sciences: 750::Oncology: 762eng
dc.subject.nsiVDP::Medisinske fag: 700::Klinisk medisinske fag: 750::Onkologi: 762nob

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs CC BY-NC-ND
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs CC BY-NC-ND